AMGN - Amgen Inc

...

Available for logged in users only.

The multiple price alert feature will smartly add or remove $1 if your alert was hit.
It's only available if you are logged in, a V.I.P. member or if you are using the AI chrome extension.

Contact us via Twitter if you are interested in trying it out.

• Amgen’s obesity prospects in focus ahead of Q4 results
• Amgen weight loss drug shows promising early data
• Earnings week ahead: Alibaba, PepsiCo, Disney, Palantir, McDonalds, Ford and more
• Catalyst watch: Alibaba earnings, World Defense Show, Fed speakers unleashed and Super Bowl buzz
• U.S. govt. opens bids in Medicare drug price negotiations
• Big Pharma earnings season in spotlight amid positive sentiment
• PBMs ramp up lobbying efforts amid growing public scrutiny
• FDA issues boxed warning for Amgen's osteoporosis drug
• Honeywell's quantum computing firm valued at $5B after new fund raising round
• Amgen may be evaluating Cytokinetics bid; CYTK wants $130-$145 a share - report (update)
• Amgen in pact with Xeris Biopharma for Tepezza injectable
• Florida wins FDA nod for mass drug imports from Canada (update)
• Morgan Stanley positive on healthcare services despite election year
• Pharma and biotech deal values spike 35% in 2023: report
• Amgen says FDA declined full approval for lung cancer drug Lumakras
• Amgen upgraded by BMO on underappreciated opportunity in obesity/metabolic space
• Dividend Roundup: Alibaba, Amgen, AT&T, Southwest Airlines, and more
• AbbVie, Amgen among firms targeted for latest Medicare inflation penalties
• Amgen names former Novartis exec James Bradner as chief scientific officer
• Amgen gets FDA priority review for small cell lung cancer drug